Drug discovery of anticancer drugs targeting methylenetetrahydrofolate dehydrogenase 2

被引：24

作者：

Asai, Ayumu ^{[1
,2
,3
]}

Koseki, Jun ^{[1
]}

Konno, Masamitsu ^{[2
]}

Nishimura, Tatsunori ^{[4
]}

Gotoh, Noriko ^{[4
]}

Satoh, Taroh ^{[2
]}

Doki, Yuichiro ^{[1
,2
,3
]}

Mori, Masaki ^{[1
,2
,3
,5
]}

Ishii, Hideshi ^{[1
,2
]}

机构：

[1] Osaka Univ, Grad Sch Med, Dept Med Data Sci, Suita, Osaka 5650871, Japan

[2] Osaka Univ, Grad Sch Med, Dept Frontier Sci Canc & Chemotherapy, Suita, Osaka 5650871, Japan

[3] Osaka Univ, Grad Sch Med, Dept Gastroenterol Surg, Suita, Osaka 5650871, Japan

[4] Kanazawa Univ, Canc Res Inst, Div Canc Cell Biol, Kanazawa, Ishikawa 9201192, Japan

[5] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka, Fukuoka 8128582, Japan

来源：

HELIYON | 2018年 / 4卷 / 12期

关键词：

Cancer research; Pharmaceutical science; Molecular biology;

D O I：

10.1016/j.heliyon.2018.e01021

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Many anticancer drugs have serious adverse effects; therefore, it is necessary to target features specific to cancer cells to minimize the effects on healthy cells. Methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) was reported to be specifically enhanced in cancer. We confirmed the validity of MTHFD2 as a drug discovery target using clinical data. In addition, we performed in silico screening to design an anticancer drug specifically targeting MTHFD2. Analysis of the clinical data indicated that MTHFD2 was enhanced in most cancers compared with normal tissues, and affected the prognosis in cancer patients. Candidate compounds for MTHFD2 inhibitors were identified using in silico drug discovery techniques, and the important interactions for MTHFD2 binding were determined. In addition, these candidate compounds decreased levels of MTHFD2 metabolites in cancer cells. The findings of the present study may help to develop anticancer drugs targeting MTHFD2, with a view to minimizing the adverse effects of anticancer drugs.

引用

页数：17

共 50 条

[1] Anticancer drug discovery by targeting cullin neddylation
Yu, Qing
Jiang, Yihan
Sun, Yi
ACTA PHARMACEUTICA SINICA B, 2020, 10 (05) : 746 - 765
[2] Anticancer drug discovery by targeting cullin neddylation
Qing Yu
Yihan Jiang
Yi Sun
ActaPharmaceuticaSinicaB, 2020, 10 (05) : 746 - 765
[3] Anticancer drug discovery targeting DNA hypermethylation
Yu, Niefang
Wang, Mingrong
CURRENT MEDICINAL CHEMISTRY, 2008, 15 (14) : 1350 - 1375
[4] Targeting Protein Tyrosine Phosphatases for Anticancer Drug Discovery
Scott, Latanya M.
Lawrence, Harshani R.
Sebti, Said M.
Lawrence, Nicholas J.
Wu, Jie
CURRENT PHARMACEUTICAL DESIGN, 2010, 16 (16) : 1843 - 1862
[5] Recent Advances in Drug Repositioning for the Discovery of New Anticancer Drugs
Shim, Joong Sup
Liu, Jun O.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2014, 10 (07): : 654 - 663
[6] Promise and challenges in drug discovery and development of hybrid anticancer drugs
Gediya, Lalji K.
Njar, Vincent C. O.
EXPERT OPINION ON DRUG DISCOVERY, 2009, 4 (11) : 1099 - 1111
[7] Harnessing Plant Biodiversity for the Discovery of Novel Anticancer Drugs Targeting Microtubules
Xie, Songbo
Zhou, Jun
FRONTIERS IN PLANT SCIENCE, 2017, 8
[8] DISCOVERY OF NEW ANTICANCER DRUGS BY COMPUTER-AIDED DRUG DESIGN
NEIDLE, S
ANNALS OF ONCOLOGY, 1994, 5 : S51 - S54
[9] ANTICANCER DRUG DISCOVERY
SIKIC, BI
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (11) : 738 - 740
[10] High-Throughput Strategies for the Discovery of Anticancer Drugs by Targeting Transcriptional Reprogramming
Huang, Lijun
Yi, Xiaohong
Yu, Xiankuo
Wang, Yumei
Zhang, Chen
Qin, Lixia
Guo, Dale
Zhou, Shiyi
Zhang, Guanbin
Deng, Yun
Bao, Xilinqiqige
Wang, Dong
FRONTIERS IN ONCOLOGY, 2021, 11

← 1 2 3 4 5 →